1223O - ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC

Date 27 September 2014
Event ESMO 2014
Session NSCLC, metastatic 1
Topics Anticancer Agents
Non-Small Cell Lung Cancer
Biological Therapy
Presenter Keunchil Park
Citation Annals of Oncology (2014) 25 (suppl_4): iv426-iv470. 10.1093/annonc/mdu349
Authors K. Park1, M. Ahn1, C. Yu2, S. Kim3, M. Lin4, V. Sriuranpong5, C. Tsai6, J. Lee7, J. Kang8, P. Perez-Moreno9, P. Button10, D. Gregory10, T.S.K. Mok11
  • 1Div Of Hem/onc, Dept Of Med, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 2Department Of Internal Medicine, National Taiwan University Hospital, Taipei City/TW
  • 3Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 4Department Of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City/TW
  • 5Division Of Medical Oncology, Chulalongkorn University, Bangkok/TH
  • 6Section Of Thoracic Oncology, Taipei Veteran General Hospital, Taipei/TW
  • 7Department Of Hematology And Medical Oncology, Seoul National University Bundang Hospital, Bundang/KR
  • 8Division Of Medical Oncology, Seoul St Mary's Hospital, Seoul/KR
  • 9Pharmaceuticals Division, Gpsmo, F. Hoffmann-La Roche Ltd, Basel/CH
  • 10Global Medical Affairs, Roche Products Pty Ltd, Sydney/AU
  • 11State Key Laboratory Of South China, Hong Kong Cancer Institute, Chinese University of Hong Kong, Hong Kong/CN



E has proven efficacy as first-line therapy for pts with EGFR mut+ NSCLC. The phase 2, open-label, single-arm ASPIRATION study assessed the efficacy of first-line E until RECIST PD, efficacy beyond PD if E was continued by the investigator, and safety in pts with EGFR mut+ NSCLC in Asia.


Pts ≥18 yrs with stage IV, EGFR mut+ NSCLC received E 150mg/day orally. Primary endpoint: PFS1 (time to RECIST PD/death). Secondary endpoints: PFS2 (time to off-E PD if E was extended beyond RECIST PD) in all pts and in pts with exon 19 deletion/L858R mutations, objective response rate (ORR), disease control rate (DCR), best objective response (BOR), PFS1 in the exon 19 deletion/L858R subset, OS and safety.


ITT population: 207 pts; 150 had a RECIST PD event at data cut-off, 46 had no PFS1, 11 withdrew, 81 continued post-PD E. Median follow-up: 213 days. PFS1: median 10.8 mo (95% CI 9.2–11.1). For pts with a RECIST PD event, data from pts receiving post-PD E vs pts not receiving post-PD E are shown in the Table. Median PFS2 (n = 81; 67 PD events): 13.0 mo (95% CI 11.5–14.8). In pts receiving post-PD E the difference between PFS1 and PFS2 was 3.7 mo. In pts with centrally confirmed exon 19 deletion/L858R mutations, median PFS1 (n = 144): 11.0 mo; median PFS2 (n = 54): 13.1 mo. ORR: 65.2%, DCR: 82.6%. OS data are immature. In the safety population (n = 207), 94 pts (45.4%) had grade ≥3 AEs, 7 (3.4%) had grade 5 AEs and 49 (23.7%) had a serious AE. The most common treatment-related AEs (grade ≥3) were skin disorders (15.9%) and GI disorders (2.9%); these were more common (all grades) in post-PD E pts vs pts not receiving post-PD E. More non-post-PD E pts (11%) had new lung lesions at PFS1 than post-PD E pts (5%).

Post-PD E N = 81 No post-PD E N = 69
PFS1*, mos 9.3 (95% CI 9.1–11.0) 7.2 (95% CI 5.4–9.2)
Depth of response*, % -49.6 -38.9
Baseline to BOR*, days 55 59
BOR to PFS1*, days 140 105
ECOG 0/1§, % 95.1 78.3§§
Grade 4 AEs§, % 2.5 7.2

*Median, n = 79, n = 61, §at PFS1, §§n = 62.


The ASPIRATION data show that continuing E beyond RECIST PD is feasible, with a difference between PFS1 and PFS2 of 3.7 mo in post-PD E pts. However, validation of the optimal pt subset to benefit from post-PD E needs further research.


K. Park: I have served on advisory boards for A-Z, BI, Clovis, EliLilly, KHK, Novartis and Roche. I have also participated in corporate sponsored research with A-Z; M. Lin: I have served on advisory boards for A-Z, Roche and Boehringer Ingelheim; J. Kang: I have served on advisory boards for Amgen and Pfizer; P. Perez-Moreno: I am an employee and stock owner of F. Hoffmann-La Roche Ltd.; P. Button: I am an employee of Roche Products Pty Ltd.; D. Gregory: I am an employee of Roche Products Pty Ltd.; T.S.K. Mok: Advisory boards: A-Z, Roche, Eli Lilly, Merck Serono, Eisai, BMS, AVEO, Pfizer, Taiho, BI, Novartis, GSK Biologicals, Clovis Oncology, Amgen Inc, Janssen and BioMarin Pharmaceutical Inc. Board of Directors: IASLC Corporate sponsored research: A-Z. All other authors have declared no conflicts of interest.